Inter Partes Review and Pharma

Here’s a video I’ve done to explain why the pharmaceutical companies’ campaign against inter partes review is disingenuous at best:

You can read more about IPRs here.

Note: There was a comment on Twitter pointing out that I don’t discuss Kyle Bass and his hedge fund’s attacks against some pharmaceutical patents using inter partes review. There are two main reasons: 1) I’ve written about Kyle Bass before, and 2) none of his petitions have gone anywhere yet and there’s no reason to think they’ll do any better than previous petitions against pharmaceutical patents.